Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

1

Neoadjuvant chemoimmunotherapy and adjuvant immunotherapy are standard treatments for resectable non-small cell lung cancer.
2

The study included 164 patients, with 37 completing the full treatment regimen and 127 not completing it.
3

No significant differences were found in recurrence-free survival or overall survival between the completed and non-completed groups.
4

Positive pathological nodal status was identified as an independent predictor of recurrence, while completion status was not.
5

The completed group had a higher incidence of any-grade adverse events, but no significant increase in severe adverse events.

Frontiers In Oncology

by Zhoujunyi Tian, Haoshuai Yang, Jin Zhang, Qiduo Yu, Deruo Liu, Meng Yang, Zhenrong Zhang, Chaoyang Liang
May 28, 2026

1